GLPwatch

Victoza vs Zepbound

Drug comparison

Last updated 2026-05-28 15:46 UTC

Victoza (liraglutide) is a once-daily injection made by Novo Nordisk for treating type 2 diabetes and reducing cardiovascular risk. Zepbound (tirzepatide), from Eli Lilly, is also given by injection but is approved for obesity and obstructive sleep apnea. Both are taken under the skin, but Victoza is used for blood sugar control while Zepbound targets weight management and sleep-related breathing issues.

AI summary of the sources below.

Victoza Zepbound
Active ingredientliraglutidetirzepatide
Manufacturernovo-nordiskeli-lilly
Routesubcutaneous injectionsubcutaneous injection
FDA-approved fortype 2 diabetes, cardiovascular risk reductionobesity, obstructive sleep apnea
Label updated2023-02-062026-04-22

Compare full details on the Victoza and Zepbound pages.